Diflunisal for ATTR cardiac amyloidosis.

Abstract

Transthyretin (TTR) cardiac amyloidosis is an important, often under-recognized and potentially modifiable cause of heart failure with a preserved ejection fraction. The only proven treatment is liver or combined heart/liver transplantation, which, although effective, is not suitable for the vast majority of older adults with this condition. Diflunisal, a nonsteroidal anti-inflammatory drug, can stabilize the TTR tetramer in vitro and may prevent misfolding monomers and dimers from forming amyloid deposits in the heart. It is one of two small molecules assessed in animal safety studies and human clinical trials of TTR polyneuropathy. The authors conducted a single-arm, open-label investigation with a mean follow-up of 0.9 ± 0.3 years to determine the safety and efficacy of diflunisal administration in a cohort of 13 patients with confirmed wild-type or mutant TTR cardiac amyloidosis. Diflunisal was well tolerated from a hematologic standpoint, although a 6% decline in estimated glomerular filtration rate was noted. Therapy was discontinued in one patient who rapidly developed volume overload. There was no significant mean change in cardiac structure (left ventricular mass: -53 g/m(2) change, P=.36), function (ejection fraction: -2% change, P=.61), or biomarkers (Troponin I: +0.03 ng/mL, P=.08; BNP: +93 pg/mL change, P=.52) during the course of therapy. These data suggest that at low dosages and with careful monitoring, diflunisal can be safely administered to compensated patients with cardiac TTR amyloidosis. Further study in a randomized placebo-controlled trial is warranted.

• Authors: Adam Castaño, Stephen Helmke, Julissa Alvarez, Susan Delisle, Mathew S Maurer
• Journal: Congestive heart failure (Greenwich, Conn.) (Congest Heart Fail) 2012 Nov-Dec Vol. 18 Issue 6 Pg. 315-9 ISSN: 1751-7133 [Electronic] United States
• PMID: 22747647 (Publication Type: Journal Article)
• Copyright: © 2012 Wiley Periodicals, Inc.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Diflunisal

Topics

• Aged
• Amyloid Neuropathies, Familial (drug therapy)
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Cohort Studies
• Diflunisal (therapeutic use)
• Female
• Heart Diseases (drug therapy)
• Humans
• Male
• Treatment Outcome